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Commentary on the role of treatment-related HIV
compensatory mutations on increasing virulence:
new discoveries twenty years since the clinical




Approximately 20 years has passed since the first human trial with HIV-1 protease inhibitors. Protease inhibitors set
the stage for combination therapy in the mid-1990s but are now rarely used in first-line combination therapy and
reserved for salvage therapy. Initially, resistance to protease inhibitors was deemed unlikely due to the small
enzymatic target with limited genetic diversity, the extended drug binding site in protease, and the need to cleave
multiple sites in the HIV-1 precursor proteins. However, a highly protease inhibitor-resistant virus can emerge
during treatment and is found to harbor a collection of primary drug-resistant mutations near the drug and/or
substrate binding site as well as secondary mutations that compensate for fitness loss. For years, the research field
has debated the impact of these secondary mutations on the emergence rates of high-level protease inhibitor
resistance. A recent study poses a more pertinent question, related to disease progression in patients newly
infected with a virus harboring secondary protease inhibitor-associated polymorphisms. The authors of that study
show that increased rates of disease progression, inferred by increased viral loads and decreased CD4 cell counts,
correlate with a fitness score of the infecting virus. The modeled fitness scores increased with an accumulation of
these secondary protease inhibitors mutations, and not because of any one specific polymorphism.
Keywords: Antiretroviral drugs, drug resistance, CD4 cell counts, fitness, human immunodeficiency virus, protease
inhibitors, viral load, virulence
Background
In 1992, I attended a Gordon Conference entitled the
‘Chemotherapy of AIDS’ in Oxnard, California. My notes
on this conference, the program, and the collection of
abstracts are buried in some dark and scary corner in my
office. Fortunately, this meeting has been etched in my
memory for the past 20 years, and not just for the good
food and inebriating beverages. Nucleoside RT inhibitors
(NRTIs) like zidovudine, didanosine, and even zalcitabine
(also known as ddC for those who forgot) were still being
tested in various dual combination therapies with three to
six months of sustained virus control [1,2]. Resistance was
rampant with even dual NRTI therapy and yet, most phar-
maceutical companies still held out a glimmer of hope
that their next antiretroviral drug would work in mono-
therapy. At this meeting, all the pharma giants rolled out
presentations on their protease inhibitors (PIs) that were
being tested in phase I or II clinical trials. I remember a
gaggle of chemists in the room begging presenters to keep
their slides up so they could quickly scratch down the var-
ious modifications on these peptidomimetic inhibitors.
Some of these PIs maintained 10-fold drops! in HIV-1
levels for up to six months without the emergence of resis-
tance [3,4]. At the time, the other new drugs on the block,
lamivudine and nevirapine, were deemed colossal failures
because viral load rebounded with a resistant HIV-1
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variant almost immediately with monotherapy [5,6]. Oh,
how times have changed. A triple drug combination ther-
apy, based on a non-NRTI (NNRTI)backbone, is now the
norm for first-line therapy and anything less than com-
plete virus suppression is deemed a treatment failure
(reviewed in [7]).
Aside from their antiviral potency on HIV in tissue cul-
ture, PIs were perceived as better than the rest because of
their small enzymatic target with a pleotropic cleavage
pattern. On average, 50 HIV-1 proteases, comprising a
198-amino acid homodimer (Figure 1A), must cleave
approximately 2,000 to 4,000 Gag and Gag-Pol proteins at
eight sites to obtain an infectious virus particle. With such
high binding affinity and selectivity of PIs for HIV-1 pro-
tease, it appeared inconceivable that this enzyme could
accommodate resistance and maintain cleavage of the nat-
ural substrates. However, the vast combination of protease
mutations associated with resistance swept away our pre-
conceived notions of HIV-1 drug resistance. One unique
feature of the mutational pattern leading to PI resistance,
which had not been readily observed in viruses with resis-
tance to NRTI or NNRTI, was the accumulation of muta-
tions outside of the substrate or inhibitor binding site [7].
As outlined in Figure 1A, primary drug-resistance muta-
tions are positioned below the ‘flap’ and near the substrate
or inhibitor binding groove (red dots in the wire frame
protease structure; Figure 1A) whereas secondary muta-
tions (for example, L10I/V, I13V, K20I/M/R, M36I, D60E,
I62V, L63P, A71T/V, V77I and I93L) are present primarily
on solvent accessible regions near the surface of the
dimer. The effects of these secondary PI mutations has
been a subject of debate for years but a recent paper by
Theys et al. in Retrovirology [8] sheds new light on how
these polymorphisms may impact disease progression in
newly infected patients.
Discussion
How do these mutations emerge under PI selection?
Most primary PI-resistance mutations may pre-exist at
low frequency in the intrapatient HIV-1 population but
their dominance with PI treatment or selection comes
with a significant fitness cost [9]. Subsequent emergence
of secondary mutations is thought to compensate or
dampen this fitness loss [10]. An alternative hypothesis
suggests that these ‘secondary’ mutations actually
emerge first under drug selection to compensate and
provide a framework for the emergence of primary
drug-resistance mutations [11]. Regardless, the pathway
to PI resistance under PI treatment is extremely com-
plex and likely affected by both the baseline protease
sequence of the HIV-1 population and additional selec-
tive pressures, for example, overlapping cytotoxic T cell
epitopes and maintaining recognition of eight cleavage
sites. As described in Figure 1B and based on the Los
Alamos HIV-1 sequence database, we now know that most
of the 99 amino acid sites are tolerant to some sequence
change in the presence or absence of PI treatment.
Initially, compensatory mutations were poorly distin-
guished from primary mutations conferring PI resistance.
A plethora of research articles identified PI treatment-
associated ‘mutations’ in treatment-naïve populations,
especially in those infected with non-subtype B HIV-1 [7].
Thus, the impact of these secondary mutations (which
could also be wild-type sequence for some HIV-1 sub-
types) on treatment outcome and emergence of PI resis-
tance was immediately brought into question and still
without resolution to date. However, a more important
role for these secondary mutations may relate to replica-
tive fitness and the ability to compensate for the fitness
loss associated with primary PI-resistance mutations. In
absence of the primary PI-resistance mutations, these sec-
ondary mutations or polymorphism may actually increase
fitness and, as a consequence, virulence. This must be qua-
lified with a big IF because the hypothesis assumes that
replicative fitness is a direct and possibly dominant corre-
late of disease progression. I have spent the last 15 years of
my research career providing evidence to support this
virulence hypothesis [12,13] so the excellent article by
Theys et al. [8] serves my ego well.
Establishing fitness scores from the relative proportions
of HIV-1 genotypes in the human population requires the
development of a robust evolutionary framework. In a pre-
vious study [14], the frequencies of synergistic interactions
between mutational pairs in protease were compared with
the frequency of any one mutation alone, that is, the prin-
ciple behind epistasis in fitness. With protease sequences
from over 12,000 treatment-naïve and PI-treated patients,
a fitness score could be estimated for specific PR geno-
types based on their prevalence in the subtype B epidemic.
A similar approach was used to score fitness of reverse
transcriptase genotypes. Higher fitness scores were
observed in patient virus with an accumulation of these
secondary mutations rather than any single protease poly-
morphism. Higher fitness scores were also a significant
correlate of lower CD4 cell counts and higher viral loads
(Figure 2 provided by Theys et al.). Reverse transcriptase
polymorphism showed no association with these clinical
parameters.
The outcome of disease following transmission of
HIV-1 with primary drug-resistant mutations is still a
subject of great debate. In the study by Theys et al. [8],
lower fitness scores derived from primary drug-resis-
tance mutations did not correlate with higher CD4 cell
counts or lower viral loads in treatment-naïve patients.
The fitness cost of deleterious, escape mutations within
a virus appears highly dependent on the time of selec-
tion pressure, relative appearance of the escape, and the
rate of subsequent diversifying evolution that can lead
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Figure 1 Schematic representation of the HIV-1 protease wireframe crystal structure and highlighting the secondary/compensatory
selected under protease inhibitor treatment. (A) The wireframe cartoon of the protease X-ray crystal structure (PDB ID:3HVP ) is present to
highlight the position of the secondary mutations (black dots) that compensate for fitness losses derived from primary drug resistance to
protease inhibitors (red dots). (B) A schematic representation of the genetic diversity in the HIV-1 protease derived from the curated HIV-1
protease alignment from Los Alamos National Laboratories HIV sequence database. Alignments of protease and any amino acid found at >1%
frequency is presented in this WebLogo (http://weblogo.berkeley.edu).
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to compensatory mutations. As we observed with emer-
gence of cytotoxic T lymphocyte-escape mutations [15],
compensation mutations rapidly emerge in HIV with a
resumption of high virus turnover and with the intrinsi-
cally high mutation rates. Thus, some transmitted HIV-1
with primary drug resistance may be more fit than others
and may not impact normal disease progression (in the
absence of treatment). Likewise, reversion of the primary
drug-resistance mutations in a background with compen-
satory mutations may result in HIV-1 that is actually more
fit than the majority of wild-type virus: the central thesis
of Theys et al. [8] If this fitness is related to virulence,
infection with HIV-1 harboring PI-associated compensa-
tory mutations may actually lead to faster disease progres-
sion as described (Figure 2) [8]. The disconcerting aspect
of this hypothesis is the probable maintenance of this
virulent HIV-1 throughout disease whereas deleterious
mutations in a defective HIV are more likely to revert
after transmission. There is, however, a fundamental con-










































































Figure 2 Relationship between HIV-1 fitness with protease inhibitor-associated compensatory mutations and (A) CD4 cell counts or
(B) viral loads. For a population of recently diagnosed drug-naïve patients, a fitness landscape was used to estimate in vivo HIV fitness under
protease inhibitor drug selective pressure. Estimated viral fitness was discretized into 10 groups, and the distribution of viral load and CD4 cell
count was plotted using boxplots. The widths of boxplot are proportional to the number of samples used. The proportion of patients with
indications of recent (acute) infection within each fitness group is shown in red.
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model. Why are these compensatory polymorphisms not
found at even higher frequencies in the treatment-naïve
HIV-1 population if they increase fitness? It is possible
that the presence of compensatory mutations requires a
specific evolutionary pathway through the fitness land-
scape. Alone, each of these polymorphisms may result in a
slight fitness cost but in order to survive, the virus must
amass these small ‘fitness hits’ to form a genotype that
might compensate for the high fitness cost of the primary
drug-resistant mutation. In this example, appearance of
this virus with higher virulence is unlikely without the PI
selective pressure directing the evolutionary pathway.
Conclusions
Theys et al. [8] may have provided the first in vivo evi-
dence that some HIV-1 mutants selected under drug pres-
sure may actually be of higher replicative fitness, which in
turn could lead to higher viral loads and lower CD4 cell
counts. Furthermore, it is naturally assumed that all evolu-
tionary pathways leading to drug resistance come with a
fitness cost, but this is not the case. The fitness cost of
NNRTI resistance is minimal at most [16] and multiple
HIV-1 lineages evolved with intrinsic NNRTI resistance,
such that mutation(s) to drug-sensitive strains actually
results in reduced replicative fitness [17]. In addition, sev-
eral HIV-1 isolates resistant to entry inhibitors, such as C-
C chemokine receptor type 5 antagonist, actually have
higher replicative fitness than the parental wild-type
strains [18]. Collectively, these observations emphasize the
need for an immediate switch in treatment regimens upon
the identification of drug resistance to avoid the emer-
gence of compensatory mutations.
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